Printer Friendly

Asahi Kasei Pharma and Eisai in Sales Promotion Agreement for Eril in China.

Tokyo, Japan, Apr 3, 2006 - (JCN) - Asahi Kasei Pharma Corporation and Eisai Co., Ltd. announced on March 31 that AKP and Eisai China Inc., a subsidiary of Eisai, signed an agreement on March 28 giving Eisai China exclusive rights to promote injectable formulations of AKP's vasodilator Eril (fasudil hydrochloride) in China.

Under the agreement, effective June 1, 2006, Eisai China will receive a commission on sales while AKP will continue to be responsible for distribution of the product to wholesalers in China.

Eril is indicated for prevention of cerebral vasospasm and ensuing cerebral ischemia following surgery for subarachnoid hemorrhage. Eril prevents blood vessels from constricting with a new mechanism that inhibits the protein kinase, which is the last step in the vasoconstriction process.

Eisai is actively concentrating on market development activities in China. In addition to the sales promotion of its own products including the globally marketed Aricept, a drug for the treatment of Alzheimer's disease, Eisai is proactively undertaking promotional activities of other companies' products.

In particular, Eisai has a solid basis for product marketing in the neurology area achieved by Aricept. The addition of Eril to the product lineup will bring greater synergy and enable further contributions to greater numbers of patients.

AKP will strengthen its business base in the Chinese market through a concentration of management resources on the osteoporosis therapy Elcitonin and the immunosuppressant Bredinin, both of which are key products in China.

The agreement announced today will enable both AKP and Eisai to gain enhanced presence in their respective fields of focus while heightening market recognition for Eril, for the ultimate benefit of the patient.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Apr 4, 2006
Words:280
Previous Article:Sharp's LR38888 Terrestrial Digital Broadcast Multimedia Processing LSI Offers Low-Power Technology with Longer Viewing Times on Mobile Devices.
Next Article:Sony Lisences 'LocationFree' Software for Windows Mobile to ACCESS.


Related Articles
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Asahi Kasei Pharma, CoTherix Conclude Licensing Agreement for Fasudil, Rho-kinase Inhibitor.
Asahi Kasei to Transfer Polystyrene Joint Venture Shares to Dow Chemical.
Asahi Kasei Announces New Plant for Compound Semiconductor Wafer Processing.
Asahi Kasei's 'Microza' Selected for Largest-scale Waterworks in the US.
Asahi Kasei Reports Consolidated Third Quarter Results; Net Sales Rise 8.8%, Net Profit Rises 22%.
Asahi Kasei Announces Revision of Plan for Year-end Dividend.
Asahi Kasei Announces Commercial Start-up of Propane-process Acrylonitrile Line.
Asahi Kasei Establishes Chinese Subsidiary to Serve as Regional Headquarters.
Asahi Kasei Announces Consolidated Full Year Results; Net Sales Rise 8.4%, Net Income Rises 15%.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |